Impact of Cytidine Deaminase Polymorphisms on Toxicity After Gemcitabine: The Question Is Still Ongoing
- 10 May 2010
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (14), e221-e222
- https://doi.org/10.1200/jco.2009.27.4928
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Cytidine Deaminase Residual Activity in Serum Is a Predictive Marker of Early Severe Toxicities in Adults After Gemcitabine-Based ChemotherapiesJournal of Clinical Oncology, 2010
- Clinical pharmacology and pharmacogenetics of gemcitabineDrug Metabolism Reviews, 2009
- Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer PatientsClinical Cancer Research, 2008
- Prolonged Versus Standard Gemcitabine Infusion: Translation of Molecular Pharmacology to New Treatment StrategyThe Oncologist, 2008
- Pharmacokinetics of Gemcitabine in Japanese Cancer Patients: The Impact of a Cytidine Deaminase PolymorphismJournal of Clinical Oncology, 2007
- TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?Trends in Pharmacological Sciences, 2006
- Decreased resistance to gemcitabine (2′,2′-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinaseBiochemical Pharmacology, 1999
- Drug resistance to 5-aza-2 ′ -deoxycytidine, 2 ′ ,2 ′ -difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cellsCancer Chemotherapy and Pharmacology, 1998